URGENT: This Altcoin Opportunity Won’t Wait – Act Now

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

Steven Rice Biography and Net Worth

Insider of Vir Biotechnology

Steven Rice has served as our Chief Administrative Officer since August 2020. Mr. Rice is responsible for human resources, legal, information technology, facilities, and employee communications. Mr. Rice held the Chief Human Resources Officer position since joining Vir in September 2019. Prior to joining Vir, Mr. Rice was the Chief Human Resources Officer for the Bill & Melinda Gates Foundation from May 2015 to May 2019 where he led human resources, facilities, events, and travel. Prior to the Bill & Melinda Gates Foundation, Mr. Rice was the Executive Vice President of global human resources at Juniper Networks, Inc. from February 2006 to May 2015. Mr. Rice also chaired Juniper Networks’ Corporate Foundation. Additionally, Mr. Rice has held several human resources leadership positions at Hewlett-Packard Company from 1981 to 2006, including Vice President of Human Resources Global Operations. Mr. Rice received his A.A. in business administration and management from De Anza College.

What is Steven J. Rice's net worth?: The estimated net worth of Steven J. Rice is at least $784,205.60 as of June 1st, 2023. Mr. Rice owns 106,840 shares of Vir Biotechnology stock worth more than $784,206 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Rice may own. Learn More about Steven J. Rice's net worth.
How do I contact Steven J. Rice?: The corporate mailing address for Mr. Rice and other Vir Biotechnology executives is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. Vir Biotechnology can also be reached via phone at 415-906-4324 and via email at [email protected]. Learn More on Steven J. Rice's contact information.
Has Steven J. Rice been buying or selling shares of Vir Biotechnology?: Steven J. Rice has not been actively trading shares of Vir Biotechnology during the last ninety days. Most recently, Steven J. Rice sold 2,500 shares of the business's stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $25.67, for a transaction totalling $64,175.00. Following the completion of the sale, the insider now directly owns 106,840 shares of the company's stock, valued at $2,742,582.80. Learn More on Steven J. Rice's trading history.
Who are Vir Biotechnology's active insiders?: Vir Biotechnology's insider roster includes Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?: In the last twelve months, insiders at the sold shares 14 times. They sold a total of 172,847 shares worth more than $1,697,678.88. The most recent insider tranaction occured on December, 2nd when EVP Verneuil Vanina De sold 76 shares worth more than $624.72. Insiders at Vir Biotechnology own 15.6% of the company. Learn More about insider trades at Vir Biotechnology.
Information on this page was last updated on 12/2/2024.

Steven J. Rice Insider Trading History at Vir Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/1/2023	Sell	2,500	$25.67	$64,175.00	106,840
2/17/2023	Sell	1,981	$25.29	$50,099.49	37,209
11/30/2021	Sell	10,000	$50.00	$500,000.00
8/23/2021	Sell	10,000	$50.00	$500,000.00	30,000
6/25/2021	Sell	3	$50.00	$150.00	20,003

Steven J. Rice Buying and Selling Activity at Vir Biotechnology

Vir Biotechnology Company Overview

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Today's Range

Now: $7.34

$7.23

$7.56

50 Day Range

MA: $8.02

$6.74

$10.17

2 Week Range

Now: $7.34

$6.56

$13.09

Volume

3,745,310 shs

Average Volume

1,084,083 shs

Market Capitalization

$1.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Most People Are Dead Wrong.

From Brownstone Research | Ad

Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.